Bayer Receives Approval for Stivarga ® in Japan for Second-Line Treatment of Hepatocellular Carcinoma (for specialized target groups only)

Stivarga ® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade / Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcin oma (HCC) with Stivarga directly after Nexavar® (sorafenib)
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news